Zavzpret (zavegepant) nasal spray receives migraine approval in USA CGRP levels in tear fluid offer new clues to migraine in women NICE draft guidance rejects rimegepant for NHS use in England Non-ictal cephalic allodynia predicts CGRP mAb response in patients with migraine Hair loss attributed to CGRP mAbs Phase 3 zavegepant data published in Lancet Neurology NICE recommends Vyepti (eptinezumab) for migraine prevention Are anti-CGRP therapies useful for paediatric migraine?

CGRP in cluster headache

22 January 2020 | Videos

In the third in his series of videos about the future of CGRP therapies, Peter Goadsby describes the research that led to the approval of galcanezumab for the treatment of episodic cluster headache and looks forward to better understanding of how treatment can be optimised for patients most likely to benefit.

Educational Partners and Supporters (others pending) Amgen

Amgen

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2023 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |